首页> Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer> Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).

Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450).

导出原文传递

翻译打印收藏纠错

第一作者： Dirk,De Ruysscher

第一单位： Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: dirk.deruysscher@maastro.nl.

作者： Dirk,De Ruysscher ^[1] ; Rinus,Wanders ^[2] ; Lizza E,Hendriks ^[3] ; Angela,van Baardwijk ^[2] ; Bart,Reymen ^[2] ; Ruud,Houben ^[2] ; Gerben,Bootsma ^[4] ; Cordula,Pitz ^[5] ; Linda,van Eijsden ^[6] ; Anne-Marie C,Dingemans ^[3]

作者单位： Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. Electronic address: dirk.deruysscher@maastro.nl. ^[1] Maastro Clinic, Maastricht, The Netherlands. ^[2] Department of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. ^[3] Department of Pulmonology, Zuyderland Hospital, Geleen, The Netherlands. ^[4] Department of Pulmonology, Laurentius Hospital, Roermond, The Netherlands. ^[5] Department of Pulmonology, Sint Jans Gasthuis, Weert, The Netherlands. ^[6]

关键词 Non-small cell lung cancer long-term survival oligometastases phase II trial